Coherus Biosciences Inc (Nasdaq:CHRS) Breaks 52 Week High Record Of $18.10

Coherus Biosciences Inc (Nasdaq:CHRS)

July 18th, 2018

Coherus Biosciences Inc closed Wednesday up 20.13%, a $3.00 increase to close on $17.90. Furthermore it hit a new 52 week high of $18.10. The stock continues to trade well at 122% of its 52 week low of $8.05. In addition to finishing higher, trading volumes were solid at 339% of normal which can indicate investors see opportunities. The next earnings report is expected in approximately 19 days.

CHRS outperformed the rest of the Healthcare sector which went up 0.08% today.

Coherus Biosciences Inc Info

Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

All amounts in USD unless otherwise indicated

CHRS daily update
CHRS daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.